Quest Diagnostics, an American clinical laboratory, completed the acquisition of Haystack Oncology, an early-stage oncology company, for $300m. "We are excited by the opportunity to work together with Haystack Oncology, a company that we believe has developed a best-in-class ctDNA MRD technology. Haystack's liquid biopsy technology, combined with Quest's strengths in screening, pathology and sequencing, will now position us to lead in the fast-growing MRD category. Working with Haystack, we have an opportunity to broaden access to MRD insights and potentially improve favorable long-term outcomes from cancer," Jim Davis, Quest Diagnostics Chairman, CEO and President.